A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) Plus Ritonavir (100mg BID) Versus Lopinavir/Ritonavir (400mg/100mg BID) When Administered in Combination with ...

Grants and Contracts Details

StatusFinished
Effective start/end date7/29/042/29/12

Funding

  • GlaxoSmithKline: $60,029.00